Breadcrumb

[A16-14] Osimertinib - Benefit assessment according to §35a Social Code Book V

Overview

Overview

Commission: Commission awarded on 2016-03-15 by the Federal Joint Committee (G-BA)
Status:Commission completed
Department/Division:Drug Assessment
Current document:PDF Extract of dossier assessment  [PDF, 312 kB]Further documents
Note:

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.

Contact address:to the contact form
Linked projects: [A18-45] Osimertinib (non-small cell lung cancer) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed

[A17-20] Osimertinib (NSCLC) - Benefit assessment according to §35a Social Code Book V
Status: Commission completed


Report documents

Report documents

PublishedDocumentSizeType 
2016-06-15 Extract of dossier assessment 312 kBPDFdownload file
2016-06-15 Dossier assessment (German version) 531 kBPDFdownload file

After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.


At a glance

Accompanying information

Extract of dossier assessment

  File-Icon  Osimertinib - Benefit assessment according to §35a Social Code Book V [PDF, 312 kB]

Federal Joint Committee (G-BA)

2016-09-15 A G-BA decision was published.

G-BA documents on this decision

Press releases

2016-06-15 Osimertinib in lung cancer: added benefit not proven



Save result list

To save your search result, please copy the link below and paste it into a new tab/window.

close